Approximately 39 million Americans are affected by migraines, according to the Modern Medicine Network.
Several drug developers are working to expand treatment options for migraines. In 2018, we'll see more activity in the specialty migraine pipeline.
According to Pharm Exec's 2018 Pipeline Report, there is a notable development in this disease area:
"Novartis and Amgen are co-developing the monoclonal antibody erenumab (AMG 334 or Aimovig), which is in Phase III studies for episodic and chronic migraines. Erenumab targets the calcitonin gene-related peptide (CGRP) receptor to block pain. A recent analysis from Novartis showed the drug reduced the number of migraine days by as much as 50% for patients who failed previous preventive therapies. Amgen has exclusive commercialization rights in Japan; Novartis has exclusive rights everywhere else."